Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Pfizer logo
PfizerPFE
1.8×+0.2×
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
5.7×+0.9×
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
3.3×+2.9×
Nuvation Bio logo
Nuvation BioNUVB
4.7×+3.2×
Immunome logo
ImmunomeIMNM
4.2×+2.3×

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Calculated from Nuvectis Pharma, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s price / book?
Nuvectis Pharma, Inc. (NVCT) reported price / book of 14.4× in Q1 2026.
How has Nuvectis Pharma, Inc.'s price / book changed year-over-year?
Nuvectis Pharma, Inc.'s price / book increased by 32.0% year-over-year, from 10.9× to 14.4×.
What is the long-term trend for Nuvectis Pharma, Inc.'s price / book?
Over 3 years (2022 to 2025), Nuvectis Pharma, Inc.'s price / book has grown at a 10.8% compound annual growth rate (CAGR), from 7.7× to 10.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.